Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
07:15am, Tuesday, 09'th Jan 2024
Sarepta Therapeutics boasts excellent innovative abilities and a deep pipeline. DexCom still has a huge growth runway left in the continuous glucose monitoring market.
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
11:18am, Friday, 05'th Jan 2024
REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial results
08:19am, Wednesday, 03'rd Jan 2024
Dyne Therapeutics Inc. shares DYN, -1.80% jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experime
New Strong Buy Stocks for January 3rd
08:16am, Wednesday, 03'rd Jan 2024
GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:30am, Tuesday, 02'nd Jan 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 42nd
Sarepta (SRPT): Strong Industry, Solid Earnings Estimate Revisions
09:46am, Friday, 29'th Dec 2023
Sarepta (SRPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
3 Things About Sarepta Therapeutics Every Smart Investor Knows
10:07am, Thursday, 28'th Dec 2023
Sarepta Therapeutics recently launched a new medicine. It already has several on the market, but the company isn't yet profitable.
Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy
12:46pm, Tuesday, 26'th Dec 2023
Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
10:15am, Friday, 22'nd Dec 2023
Sarepta Therapeutics and Vertex Pharmaceuticals already have a lot in common. Sarepta's focus market has a few peculiarities that could pose a problem.
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond
09:45am, Sunday, 17'th Dec 2023
Sarepta has encountered several issues related to its gene therapy for Duchenne muscular dystrophy. The small biotech is still generating solid financial results and has an extensive pipeline of progr
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
07:00am, Saturday, 09'th Dec 2023
Sarepta Therapeutics has multiple treatments for Duchenne muscular dystrophy, a rare genetic disorder. Its gene therapy Elevidys obtained accelerated approval this year, but recent data from a clinica
Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?
12:52pm, Friday, 01'st Dec 2023
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
09:46am, Monday, 20'th Nov 2023
We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.
3 Monster Stocks in the Making
06:49am, Saturday, 18'th Nov 2023
Beam Therapeutics develops highly promising base-editing therapies. CRISPR Therapeutics could soon have its first product on the market in the U.S. Sarepta Therapeutics is a leader in treating rare ge
